News Release

Research Articles Cites HemogloBind™ to Remove Analytical Interference from Abdominal Aorta Lysates

MONMOUTH JUNCTION, NJ, December 13, 2023 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of HemogloBind™, to remove Hemoglobin interferences prior to analysis.

Jara, Zaira Palomino, et al. "Distinct Mechanisms of β-Arrestin–Biased Agonist and Blocker of AT1R in Preventing Aortic Aneurysm and Associated Mortality." Hypertension 80.2 (2023): 385-402.

Aortic aneurysm (AA) is a “silent killer” human disease with no effective treatment. Although the therapeutic potential of various pharmacological agents have been evaluated, there are no reports of β-arrestin–biased AT1R (angiotensin II type-1 receptor) agonist (TRV027) used to prevent the progression of AA. The article states “Cleaned abdominal aortas were homogenized in T-PER Tissue Protein Extraction reagent…. Abdominal aneurysm samples were treated to remove hemoglobin captured within the vessel wall. NuGel-HemogloBind … was used according to the manufacturer protocol. …To quantify the puromycin incorporation, a standard Western blot was performed”. The article concludes TRV027-engaged AT1R prevented AA and associated mortality by distinct molecular mechanisms compared with the AT1R blocker, Olmesartan. Developing novel β-arrestin–biased AT1R ligands may yield promising drugs to combat AA.

“All of our products are species agnostic, as they not derived from immuno-affinity, so they work for all species to the best of our knowledge. Here in this example, for mice aorta lysates, HemogloBind™ improves Western blot analysis by removing Hemoglobin as an interfering component.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: Hemoglobin depletion, HemogloBind™, aortic aneurysm, β-arrestin–biased ligand, AT1R

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com